MedGenome will be at Booth #2074 to exhibit its advanced single cell sequencing and immune repertoire profiling solutions. MedGenome’s advanced analyses pipeline provides researchers with a comprehensive report which includes publication ready tables, plots and detailed metrics to visualize and interpret the results. MedGenome will also exhibit its end-to-end sequencing and informatics solutions to analyze T-cell receptor (TCR) and B-cell receptor (BCR) repertoires for antibody and diagnostics marker discovery projects.

MedGenome, Inc has been selected for the 2022 Best of Foster City Award in the Corporate Headquarters category by the Foster City Award Program.

Each year, the Foster City Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and our community. These exceptional companies help make the Foster City area a great place to live, work and play.

MedGenome and Emmes are proud to launch a strategic partnership to focus on advancing Rare Disease research.

Patients and families with rare diseases are one of the most underserved communities in medicine today. India and South Asia have the world’s largest population of people affected by rare and inherited disease.

The MedGenome – Emmes partnership will combine patients’ genomic, phenotypic and epidemiological data into custom rare disease registries.

This help bring faster and more innovative treatments to patients around the world who are suffering from rare diseases.

For more details contact:
Aditya Pai
Vice President, Corporate and Business Development at MedGenome
Email: aditya.pai@medgenome.com
Phone: (416) 452-1656

International Finance Corporation, member of the World Bank Group, is investing USD 16.5 million (around Rs 123 crore) in genetic diagnostics and research company MedGenome to increase access to COVID-19 testing in India.